The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed his research into the mechanisms of the BET protein family and T cells.
The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed his team’s research in the role of HTRA1.
Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s research on CAR T therapies.
A phase 1/2a clinical trial assessing VOR33 is currently enrolling.
Researchers are exploring gene-independent therapeutic strategies to circumvent the challenges of gene-replacement therapies.